1. Introduction {#sec1}
===============

Graves\' ophthalmopathy (GO), or thyroid eye disease (TED), is regarded as an autoimmune disorder closely related to Graves\'s disease (GD). It may cause ocular symptoms including periorbital edema, chemosis, eyelid retraction, proptosis, altered ocular motility, and even diplopia, exposure keratopathy, and dysthyroid optic neuropathy (DON), which may result in visual loss. The prevalence rate of GO ranges from 0.1% to 0.3% \[[@B1]\].

The pathogenesis of GO is still not exactly known. It is difficult to assess and manage this complicated disease. Drug therapy, radiotherapy, and eye surgery have been used to improve the symptoms according to the activity and severity of GO. Lymphocytes and inflammation may play an important part in the pathogenesis. Thus, immunosuppression therapy, especially glucocorticoids (GCs), had become the mainstay of treatment for patients with active GO, which was also recommended by the European Group on Graves\' Orbitopathy (EUGOGO) \[[@B2]\].

However, more detailed evidences were needed to support GCs as first-line treatment of GO. Therefore, we conducted a meta-analysis to compare the efficacy of GCs with other treatments for patients diagnosed with GO and to explore the ideal treatment regimen of GCs.

2. Materials and Methods {#sec2}
========================

2.1. Data Source and Search Strategy {#sec2.1}
------------------------------------

We searched randomized controlled trials (RCTs) from EMBASE, Medline, and the Cochrane library online according to a broad search strategy (S1 Strategy). The strategy included all the RCTs relevant to the glucocorticoid treatment including the monotherapy or the combined therapy with irradiation or other drugs for Graves\' ophthalmopathy referring to some protocols from previous meta-analysis \[[@B3]--[@B5]\] and Cochrane Handbook for Systematic Reviews of Interventions. A manual search was done if necessary. The electronic search covered the period from April 1966 to March 2018.

2.2. Outcome Measures {#sec2.2}
---------------------

The primary outcome was the response rate (i.e., the ratio of responders to a total number of patients) defined in each study. In addition, clinical activity score (CAS) and proptosis were also recorded to assess the therapeutic effects on the eye functions.

2.3. Trial Selection {#sec2.3}
--------------------

Two reviewers assessed the eligibility of the studies independently based on the following predetermined selection criteria: (1) study design: randomized, controlled clinical trials; (2) population: patients diagnosed with GO; (3) intervention: at least one treatment for the GO was relevant to the glucocorticoid. The studies, which compared the operative treatment with drug therapy, were not included; (4) outcome variables: at least reporting one of the three outcomes mentioned above (i.e., response rate, CAS, and proptosis). The duplicate studies were moved. Any disagreement was solved by discussing or asking the third author.

2.4. Data Extraction {#sec2.4}
--------------------

Two independent authors extracted the data from trials, respectively, by a customized form and then checked together. The following data of each study was extracted if accessible: response rate, clinical activity score, proptosis, diplopia, lid aperture/width, visual acuity, and side effects. And the characteristics or other important information was also recorded if possible: the title, authors, study design, publication year, location, inclusion and exclusion criteria, measurement point, measure methods of the recorded outcomes, and the definition of response rate mentioned in the paper. In addition, interventions, patient age, and sex as well as the number of patients lost were also included in the customized form. We estimated the data from the graphs by the software Plot Digitizer (version 2.6.8) if exact data were not accessible in the article.

2.5. Qualitative Assessment {#sec2.5}
---------------------------

The quality of included studies was appraised and described by two reviewers via a table that contained the influence factors of the bias. The qualitative assessment system was as follows: (1) allocation generation; (2) allocation concealment; (3) blinding of participants, investigators, and examiners; (4) the number of the patients lost to follow-up; (5) intension-to-treat (ITT) analysis; (6) selective reporting as described by the Cochrane Handbook; (7) other factors which would impact the bias of studies such as the equality of baseline of groups in the studies.

2.6. Statistical Analysis {#sec2.6}
-------------------------

We used the Review Manager software (RevMan, version 5.3) to conduct the statistical analysis. Risk ratio (RR) was calculated for the dichotomous variables (i.e., response rate) and mean difference (MD) for the continuous variables (i.e., proptosis) and standardized mean difference (SMD) for CAS because different clinical activity score systems were used in different trials, with 95% confidence intervals (CI). The mixture of the change-from-baseline and final value scores was included for proptosis because when using the (unstandardized) mean difference method in RevMan, it would not cause statistical problems. If any of the final value scores of CAS in the trials was unavailable in the same subgroup, the change-from-baseline value would be adopted to compare in this subgroup. When the baseline of outcome was unequal, the change-from-baseline score was also used to correct the bias. For each contrast, we estimated the heterogeneity by *χ*^2^ test and I^2^ metrics, and P \< 0.1 or I^2^\> 50% indicated the significant heterogeneity, in which case we would search for the reasons for obvious heterogeneity and chose a random effects model to analyze the combined results; otherwise we chose the fixed effects model. We estimated the mean and standard deviation (SD) through the data of median and range if necessary using the method reported by StelaPudarHozo, etc \[[@B6]\]. We included the data of the worse one if both sides of eyes were measured separately in the study.

3. Results {#sec3}
==========

Twenty-nine trials were included in our meta-analysis. The selection process was shown in the flow diagram (S2 Diagram). And the characteristics of RCTs are summarized in [Table 1](#tab1){ref-type="table"}. Patients of included studies had active GO in twenty-three trials, moderate to severe GO in twenty trials, and severe GO in one trial. The quality assessment of included studies is presented in [Table 2](#tab2){ref-type="table"}. It should be noticed that patients in study Kahaly1986 were assigned on the basis of the year of birth. The adverse events and additional treatment during follow-up period are summarized in S3 Side-effects. The results would be presented by different interventions as follows.

3.1. Corticosteroids vs. Placebo {#sec3.1}
--------------------------------

Two studies \[[@B7], [@B8]\] compared corticosteroids with placebo or control. Treatment with corticosteroids showed better curative effects in response rate; the pooled RR is 1.72 (95%CI: 1.28\~2.31, P=0.0003), with heterogeneity (I^2^=63%). Methylprednisolone was administered intravenously to active moderately severe GO patients in the study van Geest2008 \[[@B8]\], which also proved marginal effects on reduction of CAS (95% CI: −2.27\~-0.00), but no obvious effects on proptosis. Subconjunctival triamcinolone injections were administrated to inactive GO patients in study Lee2012 \[[@B7]\]. There were no major events during corticosteroid treatment (S3 Side-effects). 19 and 7 additional treatments were needed in placebo and corticosteroids group, respectively, during follow-up period.

3.2. Corticosteroids vs. Other Nonsurgical Therapy {#sec3.2}
--------------------------------------------------

Eight studies compared corticosteroids alone with other nonsurgical therapy including radiotherapy \[[@B9]\], rituximab \[[@B10], [@B11]\], cyclosporine \[[@B12]\], colchicine \[[@B13]\], immunoglobulin \[[@B14]\], mycophenolate mofetil (MMF) \[[@B15]\], and somatostatin \[[@B16]\]. And except for the rituximab, all of them reported the response rate.

The sensitive analysis indicated that the study Ye2016, \[[@B15]\] which compared the methylprednisolone with MMF, increased the I^2^ value of heterogeneity from 8% to 69%. The MMF performed better in response rate (RR = 0.74, 95%CI: 0.63\~0.88, P = 0.0005) ([Figure 1](#fig1){ref-type="fig"}) and reduction of CAS and proptosis ([Figure 2](#fig2){ref-type="fig"}) compared with GCs. On the contrary, the response rate of GCs was similar to immunoglobulin, colchicine, somatostatin, and radiotherapy and better than cyclosporine; in addition, GCs did not work better in proptosis reduction (MD = 0.42, 95%CI = 0.00\~0.85, P = 0.05) ([Figure 2](#fig2){ref-type="fig"}).

Compared with systematic methylprednisolone treatment (total 4.5g), rituximab local injections did not work better in CAS or proptosis reduction in one study \[[@B11]\]. However, in another study, \[[@B10]\] systematic rituximab treatment was more effective in reduction of CAS than methylprednisolone treatment (total 7.5g) (SMD = 0.78, 95%CI: 0.05\~1.52).

3.3. Combined Therapy vs. Monotherapy {#sec3.3}
-------------------------------------

Corticosteroid was combined with cyclosporine, \[[@B17]\] ciamexone, \[[@B18]\] technetium-99 methylene diphosphate (^99^Tc-MDP) \[[@B19]\], mycophenolate \[[@B20]\], or radiotherapy \[[@B21]--[@B23]\]. The result indicated that the combination of radiotherapy did not show extra effects compared with GCs alone (response rate, RR=1.25, 95%CI: 0.91\~1.73, P=0.17) ([Figure 1](#fig1){ref-type="fig"}). On the contrary, combination of mycophenolate improved the response rate (RR=1.47, 95%CI: 1.09\~2.00, P=0.01) and ^99^Tc-MDP or cyclosporine improved the proptosis (P\<0.00001 and P=0.02).

3.4. Ideal Regimen of Corticosteroids Therapy {#sec3.4}
---------------------------------------------

### 3.4.1. Intravenous Corticosteroids vs. Oral Corticosteroid {#sec3.4.1}

Six trials \[[@B24]--[@B29]\] compared intravenous glucocorticoids (IVGC) with oral glucocorticoids (ORGC) alone. IVGC were significantly better than ORGC in improvement of response rate (RR=1.49, 95%CI: 1.25\~1.77, P\<0.00001) ([Figure 1](#fig1){ref-type="fig"}) and CAS (SMD=-0.64, 95%CI: −1.12\~-0.16, P=0.010) ([Figure 3](#fig3){ref-type="fig"}). There were six major adverse events recorded in oral group and none in the IVGC group (S3 Side-effects). And for the proptosis, there were no significant differences between two groups (MD = -0.28, 95% CI: −0.66\~0.09, P = 0.14) ([Figure 2](#fig2){ref-type="fig"}).

### 3.4.2. Different Doses and Protocols {#sec3.4.2}

Three regimens were mentioned in two trials \[[@B30], [@B31]\]: (1) monthly: 0.5g daily for 3 consecutive days in weeks 1, 5, 9, and 13 for a total dose of 6.0g over 3 months; (2) weekly: 0.5g weekly for 6 weeks, followed by 0.25g weekly for 6 weeks for a total dose of 4.5g over 12 weeks; (3) daily: 0.5g daily for 3 consecutive days per week for 2 weeks, followed by 0.25g daily for 3 consecutive days per week for another 2 weeks and by tapering oral prednisone. Weekly protocol was more effective than daily protocol and showed less adverse events than the other two protocols. Another trial \[[@B32]\] compared three different cumulative dosages of GCs and higher cumulative dosage (7.47g) provided a transient advantage. But considering the greater toxicity of higher dose, the intermediate-dose regimen (4.98g) was recommended.

### 3.4.3. Others {#sec3.4.3}

Of the remaining three RCTs, one of them \[[@B33]\] compared the IVGC plus radiotherapy with ORGC plus radiotherapy, of which the result affirmed the advantage of IVGC against ORGC. Another trial \[[@B34]\] compared ORGC with peribulbar triamcinolone acetonide injection, which showed comparable effects. The other \[[@B35]\] proved the efficacy of dexamethasone instead of methylprednisolone.

4. Discussion {#sec4}
=============

Immunosuppressant drugs are often used to treat GO, with glucocorticoids being the most common choice in the past decades depending on its anti-inflammatory function. However, it is still a challenge for us to manage GO with GCs for the following reasons. First, if it will be beneficial to receive another immunomodulatory drug instead of GCs to manage GO which is not clear. Second, the regimen of GCs, ranging from the administration route and drug dosage to the drug administration time, varied from study to study. In the present study, we performed a meta-analysis entirely around the usage of GCs in GO including twenty-nine RCTs, to help in confronting the challenge mentioned above.

The RCTs confirmed the effect of GCs whether given systemically or by local route. Compared with the placebo or observation group, GCs group had better response rate. GCs decreased the activity of GO in active GO patients and improved the eyelid swelling and retraction in recent-onset inactive ones. And most importantly, GCs treatment reduced the need for additional treatment such as ophthalmologic surgery.

Various nonsurgical therapies such as radiotherapy, colchicine, immunoglobulin, somatostatin rituximab, MMF, and cyclosporine were compared with GCs treatment; however, most of them have similar or inferior effects except MMF. However, the obvious advantage of MMF over GCs was only proved by one study and needs more RCT to confirm it. Therefore, it is still reasonable to regard GCs as first-line treatment for active moderate to severe GO. Considering its side effects, the usage of GCs depends on the health condition of patients and should be monitored to avoid serious side effects especially on liver function, glycaemia, and mood disorder.

A part of GO patients was not responsive to GCs treatment or relapsed after the withdrawal of GCs. Thus, combined therapy was taken into consideration. The combination of radiotherapy and GCs was not superior to GCs alone according to the results. As mentioned above, the effect of GCs treatment in proptosis improvement is not obvious. Firstly, GCs did not alleviate the proptosis more obviously compared with the placebos or other nonsurgical therapies. Secondly, although the IVGC performed better than ORGC, there still was not significant difference between these two groups in the reduction of proptosis. Thus, if the proptosis is the main symptom of patient, the combination of ^99^Tc-MDP or cyclosporine may be taken into consideration with cautious control of side effects.

Corticosteroids can be administered orally, intravenously, or locally, but locally administered corticosteroids, like subconjunctival or retrobulbar injections, may result in injuries, need more operative skills, and were not proved to be more effective, so they are not recommended first. Intravenous injection of GCs worked better than oral GC in response rate and CAS improvement, in accordance with the result reported by previous meta-analysis \[[@B36]--[@B38]\], which may be ascribed to rapidly increased and higher concentration of GCs in blood. Furthermore, intravenous injection of GCs also keeps patients healthy for a longer time and results in less advanced events. The result did not change when combined with radiotherapy. Therefore, the treatment of intravenous GCs should be recommended for active moderate to severe GO patients as suggested by the consensus made by EUGOGO. A few trials explored the optimal regimen of GCs, and the intermediate-dose (cumulative doses of 4.98g) and weekly protocol were recommended which however need more evidence.

In addition, it will be valuable to carry out more trails to confirm the advantage of MMF against GCs because it was proved obviously superior to GCs no matter as monotherapy or combination with GCs.

Our meta-analysis was also limited by some factors especially the small number of included studies. We used response rate, CAS, and proptosis as outcome measures. However, some studies only reported part of the outcomes. The characteristics of included studies are shown in [Table 1](#tab1){ref-type="table"}. Most subjects recruited in the trials were active moderate to severe GO patients; therefore, the result of our analysis should be more suitable for this kind of patients. The quality of trails is summarized in [Table 2](#tab2){ref-type="table"}. All of the trials were randomized controlled trails, but study Kahaly1986 was assigned on the basis of the year of birth, which would contribute to the inadequate allocation and the bias of study. What is more, the different dosage of GCs between studies comparing the GCs with other monotherapies can also bring the bias. Last, the number of RCTs was too small to support another drug as substitution for GCs or to guide the ideal regimen of GCs.

5. Conclusion {#sec5}
=============

Our meta-analysis confirmed the effects of GCs in the management of GO and intravenous GCs is proved to be better than oral GCs as ever reported. Combination of radiotherapy and GCs did not show extra effects compared with GCs alone. However, if proptosis is the main issue, combination of ^99^Tc-MDP or cyclosporine with GCs may be taken into consideration. Recently, there have not been any suitable drugs for substitution of GCs; however, the reported advantage of mycophenolate mofetil over GCs is noteworthy and needs more RCTs to confirm.
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![**Forest plot of the response rate.**The study Ye2016 was excluded when we combined the trails and its weight was 0% in the figure. SD: standard deviation. GCs: glucocorticoids. IVGC: intravenous injection of glucocorticoids. ORGC: oral glucocorticoids.](BMRI2018-4845894.001){#fig1}

![**Forest plot of proptosis.**The study Ye2016 was excluded when we combined the trails and its weight was 0% in the figure. SD: standard deviation. GCs: glucocorticoids. Combination: the combination of GCs treatment with another therapy. IVGC: intravenous injection of glucocorticoids. ORGC: oral glucocorticoids.](BMRI2018-4845894.002){#fig2}

![**Forest plot of clinical activity score.**SD: standard deviation. GCs: glucocorticoids. IVGC: intravenous injection of glucocorticoids. ORGC: oral glucocorticoids.](BMRI2018-4845894.003){#fig3}

###### 

The characteristics of including studies.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**               **Location**        **Length**    **Age**   **Sex** \       **Stage**                                            **Prior treatment (n)**                     **Treatment group**         **Control group**                              
                                                                      **(M/F)**                                                                                                                                                                                   
  ----------------------- ------------------- ------------- --------- --------------- ---------------------------------------------------- ------------------------------------------- --------------------------- ------------------- -------------------------- ----
  van Geest2008           Utrecht             12            47.3      3/12            Active, moderately severe                            Untreated                                   GCs                         6                   Placebo                    9

  Lee2012                 Korea               6             43.5      12/83           Inactive                                             No GCs or OR                                GCs                         75                  Observation                59

  Salvi2015               Italy               6             51.1      5/26            Active, moderate to severe                           No GCs or cell depleting therapy            GCs                         16                  Rituximab                  15

  Savino2014              Italy               5             56.8      6/13            Active, moderately severe                            No GCs                                      GCs                         10                  Rituximab                  9

  Prummel1993             Netherlands         6             46.8      9/47            Moderately severe                                    Untreated                                   GCs                         28                  OR                         28

  Prummel1989             Netherlands         3             50.5      10/26           Severe                                               Untreated                                   GCs                         18                  Cyclosporine               18

  Stamato2006             Brazil              3             42.4      8/14            Active, moderate to severe                           Untreated                                   GCs                         11                  Colchicine                 11

  Kahaly1996              Germany             5             47.5      9/31            Active                                               GCs/irradiation: 20                         GCs                         19                  Immunoglobulin             21

  Ye2016                  Nanjing             6             41.1      52/106          Active, moderate to severe                           Immunosuppressive or radiotherapy: 0        GCs                         78                  Mycophenolate mofetil      80

  Kung1996                Hong Kong           3             42.1      9/9             Moderately severe                                    NA                                          GCs                         10                  Octreotide                 8

  Kahaly1986              Germany             12            46.8      5/35            NOSPECS III-V                                        18 GCs, 3 irradiation, 1 cyclophosphamide   GCs+ cyclosporine           20                  GCs                        20

  Kahaly2018              Germany and Italy   9             51.4      39/125          Active, moderate to severe                           Immunosuppressive treatment: 0              GCs+ mycophenolate          73                  GCs                        68

  Chen2016                China               3             33.6      26/70           Active                                               NA                                          GCs+^99^Tc-MDP              74                  GCs                        70

  Kahaly1990              Germany             6             51.0      9/42            Active, NOSPECS II-VI                                Steroids/radiation: 40                      GCs+ ciamexone              26                  GCs                        25

  Ng2005                  Hong Kong           13            56.2      10/6 (1 died)   Active, moderate to severe                           Untreated                                   GCs + OR                    8                   GCs                        7

  Pinchera1987            Italy               26            44        11/13           Active                                               NA                                          GCs + OR                    12                  GCs                        12

  Rajendram2018           UK                  12            49.3      33/93           Active moderate-to-severe                            Immunosuppressive or radiotherapy: 0        GCs + OR                    50                  GCs                        54

  Roy 2015                India               12            37.3      24/38           Active, moderate to severe                           Untreated                                   iv GCs                      31                  oral GCs                   31

  Macchia2001             Italy               Treat after   43.6      11/40           NA                                                   Untreated                                   iv GCs                      25                  oral GCs                   26

  Akarsu2011              Turkey              6             28.9      12/21           Active, moderately severe                            NA                                          iv GCs                      18                  oral GCs                   15

  Aktaran2007             Turkey              3             42.7      24/28           Active, moderately severe                            Untreated                                   iv GCs                      25                  oral GCs                   27

  Kahaly2005              Germany             3             50        21/49           Active, moderately severe                            Untreated                                   iv GCs                      35                  oral GCs                   35

  Kauppinen-Makelin2002   Finland             3             46.3      2/31            Active, or proptosis or diplopia                     NA                                          iv GCs + oral GCs           18                  oral GCs                   15

  Marcocci2001            Italy               12            49        14/68           Active, severity: defined by ocular manifestations   GCs/ciclosporin/octreotide / surgery: 12    iv GCs + OR                 41                  oral GCs + OR              41

  Alkawas2010             Egypt               6             NA        8/16            Active, proptosis                                    Untreated                                   oral GCs                    12                  GCs injection              12

  Bartalena2012           8 EUGOGO centers    3             52.9      33/73           Active, moderate to severe                           Untreated                                   IVMP (total 7.47g)          52                  IVMP (total 4.98g)         54

  He2016                  China               3-3.25        41.8      14/26           CAS≥3/7 or prolonged T2RTs; Moderate to severe       Untreated                                   IVMP monthly (total 6.0g)   17                  IVMP weekly (total 4.5g)   15

  Zhu2014                 China               3             46.8      34/46           Active, moderate to severe                           Immunosuppressive or radiotherapy: 0        IVMP weekly                 39                  IVMP daily                 39

  Philip2013              India               3             37.5      5/16            Active, moderate to severe                           NA                                          Dexa                        11                  IVMP                       10
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Length: the time when final values included in our analysis were measured and represented as the number of months. GCs: glucocorticoids; OR: orbital radiotherapy; IVMP: intravenous methylprednisolone; iv: intravenous; N: numbers. Dexa: dexamethasone.

###### 

Methodological quality of randomized clinical trials included in the meta-analysis.

  **Study**               **Allocation generation;  ** **concealment**   **Binding**   **Follow-up lost (n)**   **ITT**   **Selective Reporting**   **Unequal baseline or other remarks**        
  ----------------------- ---------------------------------------------- ------------- ------------------------ --------- ------------------------- --------------------------------------- ---- --------------------------------
  van Geest2008           A, A                                           Y             N                        Y         1 at week 0               Y                                       NA    
  Lee2012                 A, B                                           N             N                        Y         10                        N                                       N    Swelling grade
  Salvi2015               A, B                                           Y             N                        Y         1                         N                                       Y    Protocol amendment
  Savino2014              B, B                                           N             N                        N         1                         N                                       NA    
  Prummel1993             A, B                                           Y             N                        Y         3                         N                                       NA    
  Prummel1989             A, B                                           N             N                        Y         0                         Y                                       NA    
  Stamato2006             A, B                                           Y             N                        Y         3                         N                                       NA    
  Kahaly1996              A, B                                           N             N                        Y         0                         Y                                       NA   Visual acuity
  Ye2016                  A, B                                           N             N                        Y         16                        N                                       NA    
  Kung1996                A, B                                           N             N                        Y         0                         Y                                       NA   CAS
  Kahaly1986              C, C                                           N             N                        Y         0                         Y                                       NA    
  Kahaly2018              A, A                                           N             Y                        Y         23                        N                                       N     
  Chen 2016               A, B                                           N             N                        N         0                         Y                                       NA    
  Kahaly1990              B, B                                           Y             N                        Y         0                         Y                                       NA    
  Ng2005                  B, B                                           N             N                        Y         1                         N                                       NA   Age
  Pinchera1987            A, B                                           N             N                        N         0                         Y                                       NA    
  Rajendram2018           A, B                                           Y             Y                        Y         69                        Y                                       N    Ethnicity
  Roy2015                 A, B                                           N             N                        N         3                         N                                       N    Diplopia, TSH
  Macchia2001             B, B                                           N             N                        N         0                         Y                                       NA   CAS, OI
  Akarsu2011              B, B                                           N             N                        N         0                         Y                                       NA    
  Aktaran2007             A, A                                           N             N                        Y         0                         Y                                       NA   Lid width
  Kahaly2005              A, B                                           N             N                        Y         0                         Y                                       NA   Lid width
  Kauppinen-Makelin2002   A, A                                           N             N                        N         0                         Y                                       NA   TSab titers, visual acuity
  Marcocci2001            A, B                                           N             N                        Y         0                         Y                                       NA    
  Alkawas2010             B, B                                           N             N                        N         5                         N                                       NA    
  Bartalena2012           A, A                                           Y             N                        Y         6                         Y                                       NA   Age, gender
  He2016                  A, B                                           N             N                        Y         8                         N                                       NA    
  Zhu2014                 A, A                                           N             N                        N         2                         Y                                       NA   Duration of eye symptoms; TRAb
  Philip 2013             B, B                                           N             N                        N         0                         Y                                       NA    

ITT: intention to treat analysis; A: adequate; B: unknown; C: inadequate; N: no; Y: yes; NA: unable to assess; CAS: clinical activity score; TSH: thyroid stimulating hormone; OI: ophthalmopathy index score; TSab: thyroid stimulating antibodies; TRAb: TSH receptor antibody.
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